Hancock Jaffe Laboratories Inc (HJLI)
Hancock Jaffe Laboratories Inc
NASDAQ:HJLI (9/30/2021, 7:00:02 PM)
After market: 10.05 -0.33 (-3.18%)10.38
-0.21 (-1.98%)
Company Profile
Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 19 full-time employees. The company went IPO on 2018-05-31. The firm is engaged in developing tissue based devices that are designed for patients with cardiovascular disease, and peripheral arterial and venous disease. The firm's product includes VenoValve and CoreoGraft. VenoValve is a device surgically implanted in the deep venous system of the leg to treat a debilitating condition called chronic venous insufficiency (CVI). CoreoGraft is a bovine based conduit to be used to revascularize the heart during coronary artery bypass graft (CABG) surgeries.
Company Info
Hancock Jaffe Laboratories Inc
70 Doppler
Irvine CALIFORNIA 92618
P: 19492612900.0
CEO: Robert Berman
Employees: 19
Website: http://www.hancockjaffe.com/
HJLI News
3 years ago - enVVeno Medical Corporation enVVeno Medical Corporation Successfully Completes RebrandingCompany Now Trading Under Ticker Symbol "NVNO" IRVINE, CA / ACCESSWIRE / October 1, 2021 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease, announced today that it has successfully completed its rebranding and that its shares are now trading under the ticker symbol "NVNO" on The Nasdaq Capital Market. The Company was formerly called Hancock Jaffe
3 years ago - Hancock Jaffe Laboratories, Inc.Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg ThalmannLive webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, today announced that Robert Berman, CEO of Hancock Jaffe will
3 years ago - Hancock Jaffe Laboratories, Inc.Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 - - Development strategy to focus on venous disease and advancement of the VenoValve® - - Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 - - Management to host a conference call with live video webcast at 4:30 p.m. ET today, September 21st - IRVINE, CA /
3 years ago - Hancock Jaffe Laboratories, Inc.Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021Conference call with live video webcast to be held on Tuesday, September 21st at 4:30 p.m. ET IRVINE, CA / ACCESSWIRE / September 15, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a developer of medical devices that restore cardiac and vascular health, today announced that Hancock Jaffe management will host a corporate update conference call with a live video webcast on Tuesday, September 21, 2021 at
3 years ago - Hancock Jaffe Laboratories, Inc.Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ RulesIRVINE, CA / ACCESSWIRE / September 7, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has entered into a definitive agreement with a fund managed by Perceptive Advisors, a leading life sciences investment firm, to purchase $20 million of its common stock and pre-funded warrants in a registered direct offering priced at-the-market under Nasdaq
3 years ago - Hancock Jaffe Laboratories, Inc.Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual MeetingTwo-year VenoValve® data shows average improvements in reflux, disease manifestations and pain, of 63%, 60%, and 93%, respectively Patients with venous ulcers who experienced dramatic ulcer healing had no venous ulcer recurrences No safety issues occurred during the one-year reporting period following the study completion IRVINE, CA / ACCESSWIRE / August 19, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the
HJLI Twits
Here you can normally see the latest stock twits on HJLI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
